Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbvie Revenues up 4% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Abbvie Revenues up 4% in the Quarter

Global Humira revenues down 3%, while Skyrizi and Rinvoq sales up 64% and 54%, repectively.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Financial Report: Abbvie
1Q Revenues: $13.5 billion (+4%)
1Q Earnings: $4.5 billion (+26%)
Comments: Immunology portfolio sales were $6.1 billion, up 7% in the quarter. Humira revenues were $4.7 billion, down 2.7%. U.S. Humira revenues were $3.99 billion, an increase of 2.2 percent. Internationally, Humira revenues were $743 million, a down of 22.6%, due to biosimilar competition. Global Skyrizi sales were $940 million, an increase of 63.7%. Global Rinvoq revenues were $465 million, an increase of 53.6%. Hematologic oncology portfolio sales were $1.6 billion, a decrease of 1.6%. Global Imbruvica sales were $1.17 billion, a decrease of 7.4%, with U.S. sales of $874 million and international profit sharing of $299 million. Global Venclexta revenues were $473 million, an increase of 16.9%. Global revenues from the neuroscience portfolio were $1.48 billion, an increase of 19.2%. Global Botox Therapeutic revenues were $614 million, an increase of 15.4%. Vraylar sales were $427 million, up 23.4%. Global Ubrelvy revenues were $138 million. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters